Esplenomegalia. DG. Daniela Gomez Levy. Updated 13 September Transcript. Funciones de bazo. Aumento de las necesidades funcionales. falciforme e persistência da esplenomegalia (Doença SC, S- β-talassemia) podem ram que 1/3 desses pacientes desenvolve hiperesplenismo. Em estudo . Download Citation on ResearchGate | On Mar 31, , Henry Mauricio Rodríguez and others published Esplenomegalia criptogénica con hiperesplenismo.
|Published (Last):||8 January 2008|
|PDF File Size:||15.71 Mb|
|ePub File Size:||14.73 Mb|
|Price:||Free* [*Free Regsitration Required]|
To improve our services and products, we use “cookies” own or third parties authorized to show advertising related to client preferences through the analyses of navigation customer behavior.
Gastrointestinal bleeding is the most important clinical manifestation and patients without liver enzyme elevation seem more prone to bleed. Contact Help Who are we?
In the study period a total of 22 patients male – 17; mean age – CiteScore measures average citations received per document published.
Potential factors associated with gastrointestinal bleeding were analyzed. You can change the settings or obtain more information by clicking here.
Previous article Next article. From Monday to Friday from 9 a. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Subscribe to our Newsletter.
There were no cases of variceal rebleeding and two patients died. Sinistral, or left-sided, portal hypertension SPH is a rare entity, with multiple potential causes. Gastrointestinal variceal bleeding and hypersplenism are its’ major clinical manifestations.
Outline Masquer le plan. Specific treatment is seldom performed or needed.
Left-Sided Portal Hypertension: A Sinister Entity.
Continuing navigation will be considered as acceptance of this use. Access to the PDF text. Access to the text HTML.
Si continua navegando, consideramos que acepta su uso. Patients with clinical, radiological or laboratory alterations suggestive of cirrhosis were excluded. Esplenomegalia e inmunodeficiencia primitiva Inmunodeficiencia primitiva con hipogammaglobulinemia.
Esplenomegalia gigante y linfoma no Hodgkin
Show more Show less. Access to the full text of this article requires a subscription. The Journal publishes scientific articles of all areas within its specialty: Are you a health professional able to prescribe or dispense drugs? Acute and chronic pancreatitis are the major causes of SHP. This was a retrospective analysis of consecutive patients with present or previous diagnosis of SHP, observed in a Gastroenterology Department, in a period of 2 years. Personal information regarding our website’s visitors, including their identity, is confidential.
Subscriber If you already have your login data, please click here. February Pages SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field. Causes of SPH, clinical manifestations and outcomes were registered.
If you are a subscriber, please sign in ‘My Account’ at the top right of the screen. SRJ is a prestige metric based on the idea esplenomrgalia not all citations are the same. You can move this window by clicking on the headline. Top of the page – Article Outline. Se continuar a navegar, consideramos que aceita o seu uso. The main aim of the present study is to summarize the clinical features of patients with SPH. Print Send to esplenmegalia friend Export reference Mendeley Statistics.
Patients without liver enzymes elevation had a higher probability of gastrointestinal bleeding As per the Law relating to information storage and personal integrity, you have the right to oppose art 26 of that lawaccess art 34 of that law and rectify art 36 of that law your personal data. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal’s impact. This item has received. The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.